Maravai LifeSciences (MRVI) to Release Quarterly Earnings on Thursday

Posted by Stanley Muller on May 5th, 2026

Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) is anticipated to issue its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $52.9980 million for the quarter. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 5:00 PM ET.

Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) last posted its earnings results on Wednesday, February 25th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.03. Maravai LifeSciences had a negative return on equity of 22.79% and a negative net margin of 70.40%.The firm had revenue of $49.87 million for the quarter, compared to analysts’ expectations of $49.06 million. On average, analysts expect Maravai LifeSciences to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Maravai LifeSciences Trading Up 0.8%

Shares of MRVI traded up $0.03 during mid-day trading on Tuesday, hitting $3.82. 172,834 shares of the company’s stock traded hands, compared to its average volume of 1,478,979. The company has a quick ratio of 5.69, a current ratio of 6.60 and a debt-to-equity ratio of 0.85. Maravai LifeSciences has a 1 year low of $1.95 and a 1 year high of $4.11. The firm has a market capitalization of $982.01 million, a P/E ratio of -4.25 and a beta of 0.62. The business’s 50-day moving average price is $3.28 and its 200-day moving average price is $3.38.

Institutional Investors Weigh In On Maravai LifeSciences

Several hedge funds have recently made changes to their positions in the company. Wellington Management Group LLP bought a new stake in Maravai LifeSciences in the fourth quarter worth $7,670,000. Millennium Management LLC boosted its holdings in Maravai LifeSciences by 308.7% in the fourth quarter. Millennium Management LLC now owns 1,797,052 shares of the company’s stock worth $5,840,000 after acquiring an additional 1,357,349 shares in the last quarter. Marshall Wace LLP boosted its holdings in Maravai LifeSciences by 52.3% in the fourth quarter. Marshall Wace LLP now owns 2,000,278 shares of the company’s stock worth $6,501,000 after acquiring an additional 687,253 shares in the last quarter. Cerity Partners LLC bought a new stake in Maravai LifeSciences in the fourth quarter worth $1,521,000. Finally, Goldman Sachs Group Inc. boosted its holdings in Maravai LifeSciences by 28.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,014,214 shares of the company’s stock worth $6,546,000 after acquiring an additional 442,059 shares in the last quarter. 50.25% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded Maravai LifeSciences from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $5.38.

View Our Latest Stock Analysis on MRVI

About Maravai LifeSciences

(Get Free Report)

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.